The purposes of this study are: * To determine the overall response rate of patients treated with at least 2 cycles of this regimen. * To determine the feasibility and toxicity of the combination of topotecan and docetaxel.
The main objective of this study was to determine the overall response rate of patients treated with at least 2 cycles of topotecan and docetaxel. The secondary objectives were to determine the feasibility and toxicities of this combination. The final secondary objective is overall survival for patients that received 2 or more cycles. Methods: Eligible pts with recurrent small cell lung cancer had to be at least 3 months from initial treatment. Pts received Docetaxel 30 mg/m2 IV followed by Topotecan 3 mg/m2 IV Days 1 and 8 of a 21 day cycle. Disease assessment was done every 2 cycles. Toxicity was measured each cycle.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
7
Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days
Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 \& 8 of a 21 day cycle
Aultman Hospital
Canton, Ohio, United States
To determine the overall response rate of patients treated with at least two cycles of topotecan and docetaxel
To determine the overall response rate of patients treated with at least two cycles of topotecan and docetaxel
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.